Wall Street analysts expect Axsome Therapeutics Inc (NASDAQ:AXSM) to report earnings per share (EPS) of ($0.41) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Axsome Therapeutics’ earnings, with estimates ranging from ($0.43) to ($0.39). Axsome Therapeutics posted earnings per share of ($0.31) in the same quarter last year, which indicates a negative year-over-year growth rate of 32.3%. The company is expected to issue its next earnings report on Friday, November 8th.
On average, analysts expect that Axsome Therapeutics will report full year earnings of ($1.49) per share for the current financial year, with EPS estimates ranging from ($1.54) to ($1.38). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.37) per share, with EPS estimates ranging from ($1.72) to ($0.85). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10).
Several equities research analysts have recently weighed in on the company. William Blair assumed coverage on Axsome Therapeutics in a research note on Wednesday, September 18th. They set an “outperform” rating and a $48.00 price objective for the company. HC Wainwright reissued a “buy” rating on shares of Axsome Therapeutics in a research note on Thursday. ValuEngine lowered Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Zacks Investment Research raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 7th. Finally, Guggenheim assumed coverage on Axsome Therapeutics in a research note on Wednesday, October 16th. They set a “buy” rating and a $48.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $35.13.
Shares of AXSM traded up $0.98 during trading hours on Monday, hitting $22.02. 540,700 shares of the company were exchanged, compared to its average volume of 1,509,577. The company has a market capitalization of $775.11 million, a PE ratio of -19.15 and a beta of 2.59. The company has a debt-to-equity ratio of 0.72, a current ratio of 4.18 and a quick ratio of 4.18. The firm has a fifty day simple moving average of $22.88 and a 200-day simple moving average of $22.63. Axsome Therapeutics has a one year low of $1.94 and a one year high of $30.50.
In other Axsome Therapeutics news, CFO Nick Pizzie bought 2,180 shares of Axsome Therapeutics stock in a transaction dated Thursday, September 26th. The stock was bought at an average price of $24.80 per share, for a total transaction of $54,064.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,440 shares of the company’s stock, valued at $1,002,912. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 27.50% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Axsome Therapeutics by 41.2% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the company’s stock worth $124,000 after acquiring an additional 1,400 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at about $52,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at about $72,000. Schroder Investment Management Group acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at about $76,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at about $167,000. Institutional investors own 53.07% of the company’s stock.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Further Reading: What is the Fibonacci sequence?
Get a free copy of the Zacks research report on Axsome Therapeutics (AXSM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.